Roxithromycin/Doxycycline | Roxithromycin alone | Placebo | |
---|---|---|---|
Number of patients | 101 | 97 | 94 |
Age (year), mean (SD) | 65.8 (7.9) | 67.6 (7.85) | 66.7 (8.7) |
Male, n (%) | 64 (63.37 %) | 83 (85.57 %) | 67 (71.28 %) |
Race, n (%) | |||
New Zealand European | 99 (98.02 %) | 96 (98.97 %) | 92 (97.87 %) |
Maori/Pacific Islander | 1 (0.99 %) | 1 (1.03 %) | 1 (1.06 %) |
Other | 1 (0.99 %) | 0 | 1 (1.06 %) |
Height (cm), mean (SD) | 168.6 (9.3) | 171.4 (7.95) | 169.5 (8.2) |
Weight (kg), mean (SD) | 70.85 (14.6) | 72.8 (14.8) | 74.5 (19.7) |
Smoking history, n (%) | |||
Current smoker | 36 (35.64 %) | 17 (17.53 %) | 18 (19.15 %) |
Ex-smoker | 65 (64.36 %) | 80 (82.47 %) | 76 (80.85 %) |
Average tobacco consumption (pack year), mean (SD) | 57.96 (30.8) | 54.36 (39) | 57.38 (29.5) |
Number of previous exacerbations within 2 years, mean (SD) | 5.01 (2.34) | 5.39 (2.56) | 4.93 (2.29) |
Spirometry | |||
FEV1 (l), mean (SD) | 0.85 (0.325) | 0.965 (0.455) | 0.99 (0.49) |
FEV1 (% predicted), mean (SD) | 32.53 (13.55) | 33.93 (15.3) | 35.8 (15.2) |
FVC (l), mean (SD) | 2.11 (0.78) | 2.33 (0.82) | 2.25 (0.9) |
FEV1/FVC mean (SD) | 41.54 (10) | 41.5 (10.8) | 43.7 (9.9) |
CRQ | |||
Dyspnoea, median (Min-Max) | 15 (5 – 28) | 15 (7 – 24) | 16 (6 – 31) |
Fatigue, median (Min-Max) | 15 (5 – 25) | 16 (5 – 26) | 15 (5 – 26) |
Emotional function, median (Min-Max) | 33 (13 – 47) | 33 (15 – 48) | 32 (12 – 49) |
Mastery, median (Min-Max) | 21 (5 – 28) | 21 (7 – 28) | 19 (7 – 28) |
Co-morbidity (n, %) | |||
Ischaemic heart disease | 6 (5.94 %) | 11 (11.34 %) | 13 (13.83 %) |
Hypertension | 36 (35.64 %) | 39 (40.21 %) | 33 (35.11 %) |
Abnormal liver function | 1 (0.99 %) | 1 (1.03 %) | 1 (1.06 %) |
Gastroesophageal reflux disease | 17 (16.83 %) | 15 (15.46 %) | 18 (19.15 %) |